DOP2010000194A - Derivados de oxadiazol activos sobre fosfato de esfingosina-1 - Google Patents

Derivados de oxadiazol activos sobre fosfato de esfingosina-1

Info

Publication number
DOP2010000194A
DOP2010000194A DO2010000194A DO2010000194A DOP2010000194A DO P2010000194 A DOP2010000194 A DO P2010000194A DO 2010000194 A DO2010000194 A DO 2010000194A DO 2010000194 A DO2010000194 A DO 2010000194A DO P2010000194 A DOP2010000194 A DO P2010000194A
Authority
DO
Dominican Republic
Prior art keywords
hydrogen
alkyl
active
sphingosine
phosphate
Prior art date
Application number
DO2010000194A
Other languages
English (en)
Inventor
Christopher Norbert Johnson
Jag Paul Heer
Thomas Daniel Heightman
David Nigel Hurst
John Skidmore
Ian David Wall
Emmanuel Hubert Demont
Jason Witherington
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0725120A external-priority patent/GB0725120D0/en
Priority claimed from GB0821918A external-priority patent/GB0821918D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of DOP2010000194A publication Critical patent/DOP2010000194A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/16—Benzazepines; Hydrogenated benzazepines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D267/02—Seven-membered rings
    • C07D267/08—Seven-membered rings having the hetero atoms in positions 1 and 4
    • C07D267/12—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D267/14—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Transplantation (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

de la fórmula (l) La presente solicitud describe compuestos a base de oxadiazol activos sobre 1-fosfato esfingosina (S1P) en particular útiles para tratar lupus eritematoso; A es fenilo o un anillo de heteroarilo de 5 ó 6 miembros; R1 es de hasta dos sustituyentes independientemente seleccionados de halógeno, alcoxi deC(l3), fluoroalquilo de C(13), ciano, fenilo opcionalmente sustituido, fluoroalcoxi de C(l3), alquilo de C(l6) y cicloalquilo de C(36); R2 es hidrógeno, halógeno o alquilo de C(l4); B es un anillo saturado de 7 miembros seleccionado de los siguientes: R3 es hidrógeno o (CH2)i..4MCO2H; R4 es hidrógeno o alquilo de C(l3) opcionalmente interrumpido por oxígeno.
DO2010000194A 2007-12-21 2010-06-21 Derivados de oxadiazol activos sobre fosfato de esfingosina-1 DOP2010000194A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0725120A GB0725120D0 (en) 2007-12-21 2007-12-21 Compounds
GB0821918A GB0821918D0 (en) 2008-12-01 2008-12-01 Compounds

Publications (1)

Publication Number Publication Date
DOP2010000194A true DOP2010000194A (es) 2010-08-15

Family

ID=40342566

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2010000194A DOP2010000194A (es) 2007-12-21 2010-06-21 Derivados de oxadiazol activos sobre fosfato de esfingosina-1

Country Status (29)

Country Link
US (2) US8222245B2 (es)
EP (1) EP2222669B1 (es)
JP (1) JP2011506569A (es)
KR (1) KR20100108566A (es)
CN (1) CN101945863B (es)
AR (1) AR069916A1 (es)
AU (1) AU2008339988B2 (es)
BR (1) BRPI0820131A2 (es)
CA (1) CA2710130A1 (es)
CO (1) CO6290646A2 (es)
CR (1) CR11579A (es)
DK (1) DK2222669T3 (es)
DO (1) DOP2010000194A (es)
EA (1) EA017691B1 (es)
ES (1) ES2434730T3 (es)
HK (1) HK1142062A1 (es)
HR (1) HRP20130957T1 (es)
IL (1) IL206235A0 (es)
MA (1) MA31924B1 (es)
NZ (1) NZ585996A (es)
PE (1) PE20091339A1 (es)
PL (1) PL2222669T3 (es)
PT (1) PT2222669E (es)
RS (1) RS53038B (es)
SI (1) SI2222669T1 (es)
TW (1) TWI415847B (es)
UY (1) UY31570A1 (es)
WO (1) WO2009080725A1 (es)
ZA (1) ZA201003963B (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102007026341A1 (de) 2007-06-06 2008-12-11 Merck Patent Gmbh Benzoxazolonderivate
DE102007032507A1 (de) 2007-07-12 2009-04-02 Merck Patent Gmbh Pyridazinonderivate
TWI431010B (zh) 2007-12-19 2014-03-21 Lilly Co Eli 礦皮質素受體拮抗劑及使用方法
GB0725101D0 (en) 2007-12-21 2008-01-30 Glaxo Group Ltd Compounds
GB0725102D0 (en) * 2007-12-21 2008-01-30 Glaxo Group Ltd Compounds
DE102007061963A1 (de) 2007-12-21 2009-06-25 Merck Patent Gmbh Pyridazinonderivate
GB0725105D0 (en) 2007-12-21 2008-01-30 Glaxo Group Ltd Compounds
DE102008019907A1 (de) 2008-04-21 2009-10-22 Merck Patent Gmbh Pyridazinonderivate
GB0807910D0 (en) 2008-04-30 2008-06-04 Glaxo Group Ltd Compounds
DE102008028905A1 (de) 2008-06-18 2009-12-24 Merck Patent Gmbh 3-(3-Pyrimidin-2-yl-benzyl)-[1,2,4]triazolo[4,3-b]pyridazinderivate
ES2434247T3 (es) 2008-12-22 2013-12-16 Merck Patent Gmbh Formas polimórficas novedosas de dihidrogenofosfato de 6-(1-metil-1H-pirazol-4-il)-2-{3-[5-(2-morfolin-4-il-etoxi)-pirimidin-2-il]-bencil}-2H-piridazin-3-ona y procesos de fabricación de las mismas
GB0910674D0 (en) 2009-06-19 2009-08-05 Glaxo Group Ltd Novel compounds
WO2011028927A1 (en) * 2009-09-04 2011-03-10 Allergan, Inc. Selective sphingosine-1-phosphate receptor antagonists
BR112013028886A2 (pt) 2011-05-10 2016-08-09 Gilead Sciences Inc compostos heterocíclicos fundidos como moduladores dde canal de sódio
CN102250035A (zh) * 2011-06-10 2011-11-23 北京富卡生物技术有限公司 二芳基取代-1，3，4-噁二唑化合物的合成方法和其药物用途
NO3175985T3 (es) 2011-07-01 2018-04-28
UY34171A (es) 2011-07-01 2013-01-31 Gilead Sciences Inc Compuestos heterocíclicos fusionados como moduladores del canal iónico
RU2543485C2 (ru) * 2013-02-26 2015-03-10 Андрей Александрович Иващенко Гетероциклические агонисты рецепторов желчных кислот tgr5, фармацевтическая композиция, способы их получения и применения
CN104844535A (zh) * 2014-02-13 2015-08-19 吉利德科学公司 用于制备稠合杂环离子通道调节剂的方法
AR101591A1 (es) 2014-08-20 2016-12-28 Bristol Myers Squibb Co Compuestos bicíclicos sustituidos
CA2963447A1 (en) 2014-12-01 2016-06-09 Actelion Pharmaceuticals Ltd Cxcr7 receptor modulators
JP2024506387A (ja) * 2021-02-10 2024-02-13 アイカーン スクール オブ メディスン アット マウント サイナイ 腎線維症を治療するためのオキサジアゾリルジヒドロピラノ［２，３‐ｂ］ピリジン系ＨＩＰＫ２阻害剤
EP4426285A1 (en) * 2021-11-04 2024-09-11 Valo Health, Inc. Histone deacetylase 6 inhibitor compounds and uses thereof

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3964478B2 (ja) 1995-06-30 2007-08-22 エーザイ・アール・アンド・ディー・マネジメント株式会社 ヘテロ環含有カルボン酸誘導体及びそれを含有する医薬
JPH1180026A (ja) 1997-09-02 1999-03-23 Yoshitomi Pharmaceut Ind Ltd 新規免疫抑制剤、その使用方法およびその同定方法
IL155873A0 (en) 2000-11-14 2003-12-23 Smithkline Beecham Plc Tetrahydrobenzazepine derivatives useful as modulators of dopamine d3 receptors (antipsychotic agents)
WO2003105771A2 (en) 2002-06-17 2003-12-24 Merck & Co., Inc. 1-((5-aryl-1,2,4-oxadiazol-3-yl)benzyl)azetidine-3-carboxylates and 1-((5-aryl-1,2,4-oxadiazol-3-yl)benzyl)pyrrolidine-3-carboxylates as edg receptor agonists
BRPI0410746A (pt) 2003-05-19 2006-06-27 Irm Llc compostos e composições imunossupressoras
CN1859908A (zh) * 2003-10-01 2006-11-08 默克公司 作为s1p受体激动剂的3,5－芳基、杂芳基或环烷基取代的－1,2,4－噁二唑类化合物
CA2547198A1 (en) 2003-12-17 2005-06-30 Merck & Co., Inc. (3,4-disubstituted)propanoic carboxylates as s1p (edg) receptor agonists
WO2006001463A1 (ja) 2004-06-23 2006-01-05 Ono Pharmaceutical Co., Ltd. Ｓ１ｐ受容体結合能を有する化合物およびその用途
GB0414795D0 (en) 2004-07-01 2004-08-04 Glaxo Group Ltd Compounds
WO2006047195A2 (en) 2004-10-22 2006-05-04 Merck & Co., Inc. 2-(aryl)azacyclylmethyl carboxylates, sulfonates, phosphonates, phosphinates and heterocycles as s1p receptor agonists
JP4318087B2 (ja) 2004-12-13 2009-08-19 小野薬品工業株式会社 アミノカルボン酸誘導体およびその医薬用途
BRPI0609515A8 (pt) * 2005-03-23 2017-12-26 Actelion Pharmaceuticals Ltd Composto, composição farmacêutica, e, uso de um composto
PL1863474T3 (pl) 2005-03-23 2009-04-30 Actelion Pharmaceuticals Ltd Nowe pochodne tiofenu jako agoniści receptora 1 1-fosforanu sfingozyny
WO2006115188A1 (ja) * 2005-04-22 2006-11-02 Daiichi Sankyo Company, Limited ヘテロ環化合物
CA2610310A1 (en) 2005-06-08 2006-12-14 Novartis Ag Polycyclic oxadiazoles or isoxazoles and their use as s1p receptor ligands
BRPI0615133A2 (pt) 2005-08-23 2011-05-03 Irm Llc compostos imunossupressores, composições farmacêuticas contendo os mesmos assim como referido uso
WO2007059952A2 (en) 2005-11-24 2007-05-31 Glaxo Group Limited 1-benzazepine-3-sulfonylamino-2-pyrrloridones as factor xa inhibitors
PL2003132T3 (pl) * 2006-04-03 2014-10-31 Astellas Pharma Inc Pochodne oksadiazolu jako agoniści S1P1
WO2008064337A2 (en) 2006-11-21 2008-05-29 University Of Virginia Patent Foundation Benzocycloheptyl analogs having sphingosine 1-phosphate receptor activity
GB0725101D0 (en) 2007-12-21 2008-01-30 Glaxo Group Ltd Compounds
GB0725105D0 (en) 2007-12-21 2008-01-30 Glaxo Group Ltd Compounds
GB0725104D0 (en) 2007-12-21 2008-01-30 Glaxo Group Ltd Compounds
GB0725102D0 (en) 2007-12-21 2008-01-30 Glaxo Group Ltd Compounds

Also Published As

Publication number Publication date
RS53038B (en) 2014-04-30
AU2008339988B2 (en) 2013-09-26
HK1142062A1 (en) 2010-11-26
CN101945863A (zh) 2011-01-12
JP2011506569A (ja) 2011-03-03
US20100273771A1 (en) 2010-10-28
NZ585996A (en) 2012-06-29
CN101945863B (zh) 2013-07-03
SI2222669T1 (sl) 2013-10-30
TW200940531A (en) 2009-10-01
EP2222669A1 (en) 2010-09-01
CO6290646A2 (es) 2011-06-20
DK2222669T3 (da) 2013-10-28
US20100174065A1 (en) 2010-07-08
HRP20130957T1 (hr) 2013-11-08
AU2008339988A1 (en) 2009-07-02
BRPI0820131A2 (pt) 2015-05-12
KR20100108566A (ko) 2010-10-07
AR069916A1 (es) 2010-03-03
WO2009080725A1 (en) 2009-07-02
EA201070782A1 (ru) 2010-12-30
UY31570A1 (es) 2009-05-29
EA017691B1 (ru) 2013-02-28
CA2710130A1 (en) 2009-07-02
PE20091339A1 (es) 2009-09-26
TWI415847B (zh) 2013-11-21
MA31924B1 (fr) 2010-12-01
PL2222669T3 (pl) 2014-01-31
US8222245B2 (en) 2012-07-17
IL206235A0 (en) 2010-12-30
EP2222669B1 (en) 2013-08-21
ZA201003963B (en) 2011-11-30
PT2222669E (pt) 2013-10-28
CR11579A (es) 2010-09-03
ES2434730T3 (es) 2013-12-17

Similar Documents

Publication Publication Date Title
DOP2010000194A (es) Derivados de oxadiazol activos sobre fosfato de esfingosina-1
RS53348B (en) PROCEDURE FOR THE PREPARATION OF 3-SUBSTITUTED 2-AMINO-5-HALOBENZAMIDES
EA201170096A1 (ru) Замещенные производные пиримидона
AR049418A1 (es) Derivados de heteroarilaminopirazol y composiciones farmaceuticas para el tratamiento de la diabetes.
RS51949B (en) INHIBITORI KINAZE
CO6260074A2 (es) Compuestos de 5-(4-(halo-alcoxi)-fenil)-pirimidin-2-amina y composiciones como inhibidores de cinasa
ATE293101T1 (de) Piperidine zur verwendung als orexin rezeptor antagonisten
PE20130155A1 (es) Derivados de ariletinilo
WO2008051533A3 (en) Benzimidazole compounds
CY1111308T1 (el) Παρασκευη εσλικαρβαζεπινης και σχετικων ενωσεων με ασυμμετρη υδρογονωση
PH12015501098A1 (en) Antituberculous composition comprising oxazole compounds
WO2007149448A3 (en) Pyrazinones as cellular proliferation inhibitors
ECSP088805A (es) 2-(piridin-2-il)-pirimidinas como fungicidas
EA200700758A1 (ru) Новые производные бис-азаиндолов, их получение и фармацевтическое применение в качестве ингибиторов киназ
MY146663A (en) Organic sulfur compound and its use for controlling harmful arthropod
AR061806A1 (es) Derivados de alquilpiridazina como inhibidores de 11b-hsd1 (t2d)
TW200602456A (en) Anthracene compound and organic electroluminescent device including the anthracene compound
MY137761A (en) The use of n-arylhdrazine derivatives for combating non-crop pests
MY153042A (en) Novel (6-oxo-1, 6-dihydro-pyrimidin-2-yl)-amide derivatives, preparation thereof, and pharmaceutical use thereof as akt(pkb) phosphorylation inhibitors
CR11578A (es) Derivados de oxadiazol activos e 1-fosfato de esfingosina
EA201070817A1 (ru) ПРОИЗВОДНЫЕ ИМИДАЗО[1,2-α]ПИРИДИН-2-КАРБОКСАМИДОВ, ИХ ПОЛУЧЕНИЕ И ИХ ПРИМЕНЕНИЕ В ТЕРАПИИ
HRP20040230B1 (en) Muscarinic agonists
ATE554147T1 (de) Neue organische fluoreszierende sulfonylharnstoff-benzoxazinon-pigmente
AR072118A1 (es) Derivados de pirrolidina como antagonistas de receptor de nk2
CO5700831A2 (es) Compuestos de silicio con actividad microbiocida